A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
Nuvation Bio (NUVB) just signed an exclusive license and collaboration deal with Japan based Eisai that hands Eisai taletrectinib rights across major global markets and brings Nuvation upfront, milestone and royalty income. See our latest analysis for Nuvation Bio. The Eisai agreement lands after a sharp pullback, with a 7 day share price return of 27.34% and a 30 day decline of 29.10%. However, a 90 day gain of 80.06% and a 1 year total shareholder return of 141.73% point to earlier strong momentum that has recently faded. If this kind of oncology deal has your attention, it may be a good moment to widen your watchlist and check out healthcare stocks as potential next ideas. With Nuvation Bio trading at US$6.14 alongside an average analyst price target of US$11.33 and fresh Eisai cash inflows on the table, is the recent weakness an opportunity for investors to consider, or is the market already reflecting potential future growth in the share price? On a P/B basis, Nuvation
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NYSE:NUVB) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
- Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio says preliminary Q4 and FY25 IBTROZI net product revenue was $15.7M and $24.7M [Seeking Alpha]Seeking Alpha
- Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 1/12/26 - Form 8-K
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- NUVB's page on the SEC website